(Video length 00:08:29)

The market divergence between the tech-driven Nasdaq 100 and S&P 500 wedged an over 20% year-to-date gap between these two indices. This trend is reversing this week going into Q2 earnings season, which could be the worst in over a decade, analysts are estimating. It may be time to consider pulling some profits from your most parabolic tech stocks and rotating into some underperforming cyclical names.

Stocks I will discuss: Johnson Controls (JCI - Free Report), Weyerhaeuser (WY - Free Report), and Uber (UBER - Free Report).

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83%, and +164% in as little as 2 months. The stocks in this report could perform even better.